Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CTT NEWS
HERE's THE NEWS!
Competitive Technologies to Complete Fund Raise to Support Increased Sales of Its Calmare(R) Pain Therapy Treatment
Competitive Technologies, Inc. (NYSE Amex:CTT) today announced that the Securities and Exchange Commission (SEC) has declared its S-1 Registration statement effective. This will allow CTT to proceed with its sale of 2 million shares of CTT common stock to Crisnic Fund. The fund raise will provide CTT capital to more aggressively sell its non-invasive Calmare Pain Therapy Treatment device and to increase shareholder equity toward meeting the NYSE Amex listing requirement.
Calmare(R) Pain Therapy EPR
"We continue to be gratified by the positive results physicians are having in treating patients' pain using our Calmare Pain Therapy," said John B. Nano, CTT's Chairman, President and CEO. "The growing body of evidence-based patient outcomes that shows Calmare successfully treats various types of oncologic and neuropathic pain is a real indication of the impact we can have on patients' quality of life. We know that our Calmare Pain Therapy successfully treats chronic neuropathic and oncologic pain resulting from cancer, phantom limb syndrome, failed back surgery, sciatica, spinal stenosis, shingles and other maladies.
"Just last week, Stephen J. D'Amato, MD FACEP, Medical Director of Calmar Pain Relief, LLC, in North Providence, RI, shared with me two of his most recent patient success stories. A 92-year-old woman described by her granddaughter as a 'beautiful, vibrant woman whose eternal optimism had been overshadowed by decades of debilitating back pain,' was treated by Dr. D'Amato and is now 'filled with hope and gratitude' as her pain was alleviated by Calmare treatments. Another moving story was of a teenager whose parents traveled from Texas to Rhode Island in search of this treatment. As Dr. D'Amato told me, 'When the boy was 12, he suffered an injury to his right lower leg that developed into Complex Regional Pain Syndrome (CRPS) Type 1, which he has suffered from for 5 years. I discharged him Friday after a 10-treatment cycle that resulted in 100% resolution of his pain from his mid-thigh to his ankle.' Hearing stories like these, in addition to the evidence-based clinical research presented at the American Society of Clinical Oncologists (ASCO) meeting in early June, makes it clear that we are creating a paradigm shift in how chronic pain is treated globally and making a real difference in the quality of life of individual patients."
Being able to offer physicians a non-invasive, effective method for treating chronic pain without the harmful, adverse side effects of opioids such as morphine is a key focus of CTT's mission to improve the quality of life for patients suffering from debilitating oncologic and neuropathic pain. Calmare is now being used to treat pain patients at universities including Virginia Commonwealth University's Massey Cancer Center, under the direction of Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit; the University of Wisconsin, Madison's Paul Carbone Cancer Center under the direction of Toby Campbell, M.D.; and the University of Miami's Pain Management Center, under the direction of Salahadin Abdi, MD, PhD, Professor and Chief, University of Miami Pain Management Center. Additionally, patients are being treated with Calmare at hospitals and clinics in Massachusetts, New York, Virginia, Florida, Connecticut, Rhode Island, and Utah, as well as in Europe and Asia.
The non-invasive Calmare pain therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTT's client, Professor Giuseppe Marineo. CTT's partner, GEOMC Co. Ltd. of Seoul, Korea is manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales. For more information about Calmare Pain Therapy Treatment, visit www.CalmareTT.com.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
CONTACT: IR Services, LLC
Johnnie D. Johnson
860.434.2465
jdjohnson@corpirservices.com
CTT NEWS
HERE's THE NEWS!
Competitive Technologies to Complete Fund Raise to Support Increased Sales of Its Calmare(R) Pain Therapy Treatment
Competitive Technologies, Inc. (NYSE Amex:CTT) today announced that the Securities and Exchange Commission (SEC) has declared its S-1 Registration statement effective. This will allow CTT to proceed with its sale of 2 million shares of CTT common stock to Crisnic Fund. The fund raise will provide CTT capital to more aggressively sell its non-invasive Calmare Pain Therapy Treatment device and to increase shareholder equity toward meeting the NYSE Amex listing requirement.
Calmare(R) Pain Therapy EPR
"We continue to be gratified by the positive results physicians are having in treating patients' pain using our Calmare Pain Therapy," said John B. Nano, CTT's Chairman, President and CEO. "The growing body of evidence-based patient outcomes that shows Calmare successfully treats various types of oncologic and neuropathic pain is a real indication of the impact we can have on patients' quality of life. We know that our Calmare Pain Therapy successfully treats chronic neuropathic and oncologic pain resulting from cancer, phantom limb syndrome, failed back surgery, sciatica, spinal stenosis, shingles and other maladies.
"Just last week, Stephen J. D'Amato, MD FACEP, Medical Director of Calmar Pain Relief, LLC, in North Providence, RI, shared with me two of his most recent patient success stories. A 92-year-old woman described by her granddaughter as a 'beautiful, vibrant woman whose eternal optimism had been overshadowed by decades of debilitating back pain,' was treated by Dr. D'Amato and is now 'filled with hope and gratitude' as her pain was alleviated by Calmare treatments. Another moving story was of a teenager whose parents traveled from Texas to Rhode Island in search of this treatment. As Dr. D'Amato told me, 'When the boy was 12, he suffered an injury to his right lower leg that developed into Complex Regional Pain Syndrome (CRPS) Type 1, which he has suffered from for 5 years. I discharged him Friday after a 10-treatment cycle that resulted in 100% resolution of his pain from his mid-thigh to his ankle.' Hearing stories like these, in addition to the evidence-based clinical research presented at the American Society of Clinical Oncologists (ASCO) meeting in early June, makes it clear that we are creating a paradigm shift in how chronic pain is treated globally and making a real difference in the quality of life of individual patients."
Being able to offer physicians a non-invasive, effective method for treating chronic pain without the harmful, adverse side effects of opioids such as morphine is a key focus of CTT's mission to improve the quality of life for patients suffering from debilitating oncologic and neuropathic pain. Calmare is now being used to treat pain patients at universities including Virginia Commonwealth University's Massey Cancer Center, under the direction of Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit; the University of Wisconsin, Madison's Paul Carbone Cancer Center under the direction of Toby Campbell, M.D.; and the University of Miami's Pain Management Center, under the direction of Salahadin Abdi, MD, PhD, Professor and Chief, University of Miami Pain Management Center. Additionally, patients are being treated with Calmare at hospitals and clinics in Massachusetts, New York, Virginia, Florida, Connecticut, Rhode Island, and Utah, as well as in Europe and Asia.
The non-invasive Calmare pain therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTT's client, Professor Giuseppe Marineo. CTT's partner, GEOMC Co. Ltd. of Seoul, Korea is manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales. For more information about Calmare Pain Therapy Treatment, visit www.CalmareTT.com.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
CONTACT: IR Services, LLC
Johnnie D. Johnson
860.434.2465
jdjohnson@corpirservices.com
HERE's THE NEWS!
Competitive Technologies to Complete Fund Raise to Support Increased Sales of Its Calmare(R) Pain Therapy Treatment
Competitive Technologies, Inc. (NYSE Amex:CTT) today announced that the Securities and Exchange Commission (SEC) has declared its S-1 Registration statement effective. This will allow CTT to proceed with its sale of 2 million shares of CTT common stock to Crisnic Fund. The fund raise will provide CTT capital to more aggressively sell its non-invasive Calmare Pain Therapy Treatment device and to increase shareholder equity toward meeting the NYSE Amex listing requirement.
Calmare(R) Pain Therapy EPR
"We continue to be gratified by the positive results physicians are having in treating patients' pain using our Calmare Pain Therapy," said John B. Nano, CTT's Chairman, President and CEO. "The growing body of evidence-based patient outcomes that shows Calmare successfully treats various types of oncologic and neuropathic pain is a real indication of the impact we can have on patients' quality of life. We know that our Calmare Pain Therapy successfully treats chronic neuropathic and oncologic pain resulting from cancer, phantom limb syndrome, failed back surgery, sciatica, spinal stenosis, shingles and other maladies.
"Just last week, Stephen J. D'Amato, MD FACEP, Medical Director of Calmar Pain Relief, LLC, in North Providence, RI, shared with me two of his most recent patient success stories. A 92-year-old woman described by her granddaughter as a 'beautiful, vibrant woman whose eternal optimism had been overshadowed by decades of debilitating back pain,' was treated by Dr. D'Amato and is now 'filled with hope and gratitude' as her pain was alleviated by Calmare treatments. Another moving story was of a teenager whose parents traveled from Texas to Rhode Island in search of this treatment. As Dr. D'Amato told me, 'When the boy was 12, he suffered an injury to his right lower leg that developed into Complex Regional Pain Syndrome (CRPS) Type 1, which he has suffered from for 5 years. I discharged him Friday after a 10-treatment cycle that resulted in 100% resolution of his pain from his mid-thigh to his ankle.' Hearing stories like these, in addition to the evidence-based clinical research presented at the American Society of Clinical Oncologists (ASCO) meeting in early June, makes it clear that we are creating a paradigm shift in how chronic pain is treated globally and making a real difference in the quality of life of individual patients."
Being able to offer physicians a non-invasive, effective method for treating chronic pain without the harmful, adverse side effects of opioids such as morphine is a key focus of CTT's mission to improve the quality of life for patients suffering from debilitating oncologic and neuropathic pain. Calmare is now being used to treat pain patients at universities including Virginia Commonwealth University's Massey Cancer Center, under the direction of Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit; the University of Wisconsin, Madison's Paul Carbone Cancer Center under the direction of Toby Campbell, M.D.; and the University of Miami's Pain Management Center, under the direction of Salahadin Abdi, MD, PhD, Professor and Chief, University of Miami Pain Management Center. Additionally, patients are being treated with Calmare at hospitals and clinics in Massachusetts, New York, Virginia, Florida, Connecticut, Rhode Island, and Utah, as well as in Europe and Asia.
The non-invasive Calmare pain therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTT's client, Professor Giuseppe Marineo. CTT's partner, GEOMC Co. Ltd. of Seoul, Korea is manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales. For more information about Calmare Pain Therapy Treatment, visit www.CalmareTT.com.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.
CONTACT: IR Services, LLC
Johnnie D. Johnson
860.434.2465
jdjohnson@corpirservices.com
yep, all the signal lines crossing over, it bottomed out last week and is about to make a nice steady move upward here
morning, certainly looks like it, been watching behind the scenes on this one for a few weeks now waiting for this chart set up, looks like now is the time
CTT MACD about to crossover, Full Sto and Williams %R about to turn up, looks like its go time for this one based on the chart.
Hmmm, don't see where it says that
TITLE OF EACH CLASS OF TO BE PRICE OFFERING REGISTRATION SECURITIES TO BE REGISTERED REGISTERED PER SHARE(1) PRICE(1) FEE
Common Stock, par value
0.01 per share 2,000,000 $ 2.70 $5,389,000 $ 384.24
Common Stock, par value
0.01 per share 75,000 (2) $ 3.17 $ 237,750 $ 16.95
Total 2,075,000 $5,626,750 $ 401.19
--------------------------------------------------------------------------------
(1) Estimated pursuant to Rule 457(c), solely for the purpose of calculating the registration fee based on 85% of the closing price for the common stock, as reported on the NYSE Amex Equities Stock Exchange on May 28, 2010. Under the common stock purchase agreement, Crisnic Fund SA has agreed to purchase 2,000,000 shares of newly issued CTT common stock at a price equal to 85% of the current volume weighted average market price.
CTT going to make a move
CTT going to make a move
Isn't the crisnic fund purchasing these shares at a price of about 2.70 a share, so won't they have a reasonable interest to get the share price to at least that price if not higher either before or shortly after their purchase?
Hello all, just a couple questions, when will the transaction between Crisnic and CTT take place?, do we have any idea on when the Panel is going to make a decision?
what do you think has happened here over the last few weeks? we went from .022 all the way down to the .007 area, if you don't think that that is a pullback then you better just leave, if you knew even how to look at a chart you wouldn't be saying that, this is the best the daily chart has looked yet, all indicators pointing up, i've been waiting patiently for this time to come, watch out for an exciting 2 weeks here imo
and....? what does that have to do with my post?
yep, next week should be interesting imo, given the symbol change and divi news could come at any time, richwood shipment anytime, theirs a holiday, and the daily chart is making a reversal
yes, but my point is the reason you see nite their in those situations is not necessarily because of a conspiracy theory, but more because 9/10 Nite is on the bid and the ask with this stock due to the majority of shareholders routing through him
At least we closed green guys! it's a start, 2 green days in a row and the daily is turning, looks good for next week all
wow, great excuse
yep plain and simple, how does he not just admit that he lied when the proof is in plain sight
no it hasn't, the bid was hit and that's why the ask dropped to .012, bud seriously, i've been watching the L2 all day and when the ask gets hit it moves
what about the times when he's on ask and bid and its moving up? Nite is on the ask and bid the majority of the time
Posted by: BL Date: Monday, November 02, 2009 2:23:13 PM
In reply to: BL who wrote msg# 10166 Post # of 15312 [Send a link via email]
this stock is a no brainer (ALL-IN),all the free divy's all great so let the idiots sell ,this is going to go hard imo ,have all my shares since 0.0030 and adding this dip unreal people.they will be sorry when this is .15 cents by xmas or maybe more...imo bl
thats not true at all, it was moving earlier when that was happening
WDAS .19x.20 2x1 now
WDAS .19x.20 2x1 now
WDAS .20x.225 1x2 now
WDAS .20x.225 1x2 now
WDAS .21s back on the ask now, could see a power hour push here imo
WDAS .21s back on the ask now, could see a power hour push here imo
ask moved up to .0125 now, nite's full of chit, we get consistent buying and then would fly, man i can't wait for symbol change/divi news
WDAS .194x.205 1x1 now